DOCSLIB.ORG

Dopamine Outside the Brain: the Eye, Cardiovascular System and Endocrine Pancreas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dopamine Outside the Brain: the Eye, Cardiovascular System and Endocrine Pancreas Pharmacology & Therapeutics 203 (2019) 107392 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas Claudio Bucolo 1,GianMarcoLeggio1, Filippo Drago ⁎, Salvatore Salomone Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy article info abstract Available online 9 July 2019 Dopamine (DA) and DA receptors (DR) have been extensively studied in the central nervous system (CNS), but their role in the periphery is still poorly understood. Here we summarize data on DA and DRs in the eye, cardio- Keywords: vascular system and endocrine pancreas, three districts where DA and DA-related drugs have been studied and Dopamine receptors the expression of DR documented. In the eye, DA modulates ciliary blood flow and aqueous production, which im- Heteromers pacts on intraocular pressure and glaucoma. In the cardiovascular system, DA increases blood pressure and heart Intra ocular pressure activity, mostly through a stimulation of adrenoceptors, and induces vasodilatation in the renal circulation, pos- Dopamine cardiovascular action sibly through D1R stimulation. In pancreatic islets, beta cells store DA and co-release it with insulin. D1R is mainly Somatostatin Diabetes expressed in beta cells, where it stimulates insulin release, while D2R is expressed in both beta and delta cells (in the latter at higher level), where it inhibits, respectively, insulin and somatostatin release. The formation of D2R- somatostatin receptor 5 heteromers (documented in the CNS), might add complexity to the system. DA may exert both direct autocrine effects on beta cells, and indirect paracrine effects through delta cells and somatostatin. Bro- mocriptine, an FDA approved drug for diabetes, endowed with both D1R (antagonistic) and D2R (agonistic) ac- tions, may exert complex effects, resulting from the integration of direct effects on beta cells and paracrine effects from delta cells. A full comprehension of peripheral DA signaling deserves further studies that may gener- ate innovative therapeutic drugs to manage conditions such as glaucoma, cardiovascular diseases and diabetes. © 2019 Elsevier Inc. All rights reserved. Contents 1. Introduction................................................ 2 2. Dopamineandtheeye(excludingretina).................................. 2 3. Dopamineandthecardiovascularsystem.................................. 3 4. Metabolicdisorders(diabetes)associatedwithParkinson'sdiseaseandschizophrenia:roleofmedications.....6 5. Dopamineintheendocrinepancreas.................................... 8 6. Therapeuticimplicationsintype2diabetes................................. 10 7. Concludingremarks........................................... 10 DeclarationsofCompetingInterest....................................... 10 Acknowledgments.............................................. 10 References.................................................. 10 Abbreviations: AC, Adenylyl cyclase; AH, Aqueous humor; α1AR, Alpha1-adrenoceptor; βAR, Beta-adrenoceptor; CICR, Calcium-induced calcium release; cAMP, Cyclic adenosine monophosphate; CaV, Voltage-gated Ca2+ channels; cGMP, Cyclic guanosine monophosphate; CNS, Central nervous system; DA, Dopamine; DAG, Diacylglycerol; DR, Dopamine receptor; D(1–5)R, Dopamine receptor (1–5); EC, Endothelial cell; EPAC, Exchange proteins activated by cAMP; EPI, Epinephrine; GIRK, G protein-coupled inwardly-rectifying potassium channels; GPCR, G protein-coupled receptors; GRK, G-protein-coupled receptor kinase; HAEC, Human aortic endothelial cells; HUVEC, Human umbilical vein endothelial cells; IHC, Immunohistochemistry; IOP, Intraocular pressure; IP3, Inositol 1,4,5-trisphosphate; ISH, in situ hybridization; i.v., Intravenous; L-DOPA, L-3,4-Dihydroxyphenylalanine; NE, Norepinephrine; PD, Parkinson's disease; PKA, Protein kinase A; PLC, Phospholipase C; PIP2, Phosphatidylinositol diphosphate; RT-PCR, Reverse transcription-polymerase chain reaction; sGC, Soluble guanylyl cyclase; SPET, Single-photon emission tomography; SST, Somatostatin; SSTR, Somatostatin receptor; SSTR(2–5), Somatostatin receptor (2–5); T2D, Type 2 diabetes; TH, Tyrosine hydroxylase; VMAT2, Vesicular monoamine transporter 2; VSMC, Vascular smooth muscle cell; WT, Wild-type; WB, Western blot. ⁎ Corresponding author at: Department of Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy. E-mail address: [email protected] (F. Drago). 1 Equally contributing authors https://doi.org/10.1016/j.pharmthera.2019.07.003 0163-7258/© 2019 Elsevier Inc. All rights reserved. 2 C. Bucolo et al. / Pharmacology & Therapeutics 203 (2019) 107392 1. Introduction Dopaminergic neurotransmission is implicated in the pathophysiol- ogy of major neuropsychiatric disorders, including Parkinson's disease (PD) and schizophrenia. The study of dopamine (DA) and dopaminergic transmission has contributed to the development of relevant drugs, such as L-DOPA, bromocriptine, haloperidol, clozapine, and many others, which act via dopaminergic mechanisms. Four main dopaminer- gic pathways have been identified within the central nervous system (CNS). The ventral tegmental area is the place of origin of two projection pathways towards the cortex (the mesocortical pathway) and the lim- bic area (the mesolimbic pathway); the hypothalamus is the place of or- igin of a projection towards the pituitary gland which controls prolactin secretion (the tuberoinfundibular pathway) and a dopaminergic projec- tion extends from the substantia nigra to the striatum (the nigrostriatal pathway). DA acts on specific receptors, belonging to the G protein- coupled receptor family. Five genes encoding DA receptors (DRs) have Fig. 1. Schematic illustration showing heterodimerization of dopamine D2 receptor with fi been identi ed. These receptors are divided in two subfamilies: the somatostatin receptor 5 and consequent modulation of downstream signaling. The D1-like receptor subtypes (D1R and D5R), coupled to Gs, activating formation of D2R-SSTR5 heterodimers enhances the inhibitory effect on adenylyl cyclase adenylyl cyclase and the D2-like subfamily (D2R, D3R, and D4R) (AC) and may affect additional signaling, such as mitogen-activated protein kinases coupled to Gi, inhibiting adenylyl cyclase (Missale, Nash, Robinson, (MAPK). Jaber, & Caron, 1998). D1R and D2R are the most abundant subtypes in the CNS, but D1R is the most widespread (Fremeau Jr. et al., 1991). receptors, not only they induce the suppression of G protein signaling D5R is expressed at a much lower level than D1R and its distribution (desensitization, down-regulation), but also promote G protein- is limited to the hippocampus and thalamus (the lateral mammillary independent signaling. This phenomenon has been largely studied for nucleus and the parafascicular nucleus of the thalamus) (Ciliax et al., DRs in CNS; for example, the reduced response to drugs that enhance 2000). D2R is located mainly in the striatum, olfactory tubercle, nucleus DA neurotransmission in β-arrestin 2 knockout mice indicates that β- accumbens, substantia nigra pars compacta, ventral tegmental area and arrestin 2 participates in DR signaling. In particular, β-arrestin 2 is con- pituitary gland. D2R and D3R are pre- and post-synaptic, unlike D1R and sidered to act as an intermediate in the regulation of Akt and GSK-3 fol- D5R, which are mainly post-synaptic receptors (McGinnis, Siciliano, & lowing DR stimulation (Beaulieu et al., 2005). Jones, 2016; Radl et al., 2018). D4R is found, at a lower expression, in Many studies have generated a plethora of data on DA neurotrans- the basal ganglia and at a higher expression in the frontal cortex, me- mission in the CNS, but the role of peripheral (i.e. outside the CNS) DA dulla, amygdala, hypothalamus and mesencephalon; however in these is still poorly understood. DRs outside the brain have been identified areas, D4R expression remains below the expression level of other in diverse organs and tissues, including vascular beds, heart, gastroin- DRs (Valerio et al., 1994). D3R is expressed in several brain areas (mes- testinal tract, eye, kidney and pancreas (Beaulieu & Gainetdinov, 2011; encephalon, nucleus accumbens, olfactory tubercle and islands of Bucolo et al., 2012; De Mei, Ramos, Iitaka, & Borrelli, 2009; Calleja, striatum, PFC, and hippocampus) (Leggio, Bucolo, Platania, Missale et al., 1998). Circulating DA levels attain 15–30pg/mL Salomone, & Drago, 2016). (0.1–0.2 nmol/L), coming mainly from spilling over from noradrenergic In addition to acting as monomers, DRs constitute, within and out- nerves (Goldstein & Holmes, 2008). This concentration is far below the side the brain, dimeric and/or oligomeric complexes by association of dissociation constant of DA for DRs, but it might be substantially higher a single species (homodimer, homomer) or different species (heterodi- and attain a level sufficient for DR activation in the proximity of vascular mer, heteromer); in this latter case the association may involve not only receptors, particularly those located in vascular smooth muscle cells re- different DR subtypes, but also other G protein-coupled receptors ceiving sympathetic nerve endings. Several studies also report a variable (GPCR) and even ligand-gated channels. Heteromerization has been expression and distribution of DRs in immune cells (Bergquist & documented for D1R and D2R (Lee et al.,
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Effect of Ergot Alkaloids on Bovine Foregut Vasculature, Nutrient Absorption, and Epithelial Barrier Function
    University of Kentucky UKnowledge Theses and Dissertations--Animal and Food Sciences Animal and Food Sciences 2013 EFFECT OF ERGOT ALKALOIDS ON BOVINE FOREGUT VASCULATURE, NUTRIENT ABSORPTION, AND EPITHELIAL BARRIER FUNCTION Andrew P. Foote [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Foote, Andrew P., "EFFECT OF ERGOT ALKALOIDS ON BOVINE FOREGUT VASCULATURE, NUTRIENT ABSORPTION, AND EPITHELIAL BARRIER FUNCTION" (2013). Theses and Dissertations--Animal and Food Sciences. 18. https://uknowledge.uky.edu/animalsci_etds/18 This Doctoral Dissertation is brought to you for free and open access by the Animal and Food Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Animal and Food Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Interaction of Pergolide with Central Dopaminergic Receptors (Parkinsonism/Adenylate Cyclase) MENEK GOLDSTEIN*, ABRAHAM LIEBERMAN*, Jow Y
    Proc. Natl. Acad. Sci. USA Vol. 77, No. 6, pp. 3725-3728, June 1980 Neurobiology Interaction of pergolide with central dopaminergic receptors (parkinsonism/adenylate cyclase) MENEK GOLDSTEIN*, ABRAHAM LIEBERMAN*, Jow Y. LEW*, TAKU ASANO*, MYRNA R. ROSENFELDt, AND MAYNARD H. MAKMANt *New York University Medical Center, Departments of Psychiatry and Neurology, 560 First Avenue, New York, New York 10016; and tAlbert Einstein College of Medicine, Departments of Biochemistry and Molecular Pharmacology, Bronx, New York 10461 Communicated by Michael Heidelberger, February 12,1980 ABSTRACT The activity of pergolide, an N-propylergoline MATERIALS AND METHODS derivative, has been tested for stimulation of central dopa- minergic receptors. Binding to dopamine receptors shows that Materials. [3H]Dopamine (8.4 Ci/mmol), [3H]Spiroperidol pergolide acts as an agonist with respect to these receptors. GTP ([3H]Spi) (23 Ci/mmol), N-n-[3H]propylnorapomorphine decreases the potencies of dopamine agonists and of pergolide, ([3H]NPA) (75 Ci/nmol) were purchased from New England but not of bromocriptine, to displace [3HJspiroperidol {43HSpi) Nuclear (1 Ci = 3.7 X 1010 becquerels). Pergolide was a gift from striatal membrane sites. The GTP-sensitive site labeled from Eli Lilly, and bromocriptine from Sandoz Pharmaceu- by [3HJSpi seems to be localized on intrastriatal dopamine re- tical. ceptors. The potency of dopamine agonists and of pergolide to Binding Assay. Preparation of bovine or rat membranes and displace [3HJSpi from striatal receptor sites is reduced in membranes exposed to higher temperatures. Pergolide, but not the ensuing binding assay were carried out as described (13). hitherto-tested dopaminergic ergots, stimulates do amine- For routine assay each tube contained 1.8 ml.
    [Show full text]
  • Discriminative Stimulus Properties of Lysergic Acid Diethylamide in the Monkey
    J j.Pharmacol.exp.Ther. 234_ 244-249 (1985). BC 428/LEX 827 _.34,_o.I in U.S_ Discriminative Stimulus Properties of Lysergic Acid Diethylamide in the Monkey ERIKB. PsychopharmacologicalResearch Laboratory, Sct. Hans Mental Hospital, DK-4000 Roskilde, Denmark Accepted for publication April 1, 1985 ABSTRACT Four monkeys (Cercopithecus aethiops) were trained to discrim- dose of pirenperone attenu_ited the LSD stimulus effect (to 55%). inate 0.06 mg/kg of lysergic acid diethylamide (LSD) from saline A 0.1-mg/kg dose of pirellperone produced nonresponding in in a two-key task in which correct responding was reinforced three of four animals. The I SD cue was unaffected by clozapine with food under a fixed ratio 32 schedule. The EDsoof LSD was (1 and 2 mg/kg), haloperid)l (0.1 mg/kg) and pizotifen (0.6-1.8 0.011 mg/kg. The nonhallucinogenic ergot, lisuride, and the mg/kg). The fact that lisuri:le does not readily cause hallucina- hallucinogen, 5-methoxy-N,N-dimethyltryptamine, substituted tions in humans, but yet s Jbstituted for LSD in primates, indi- completely for LSD (EDso values were 0.0098 and 0.45 mg/kg, cates that the LSD cue ma 1/not reflect the hallucinogenic prop- respectively). Mescaline (1-40 mg/kg), d-amphetamine (0.1- erties of LSD. It is suggest_l that the LSD stimulus effect may 0.625 mg/kg) and apomorphine (0.1-0.5 mg/kg) did not substi- depend on receptors (e.g. serotonergic) that, at the moment, tute for LSD. In antagonism testing with ketanserin (1-10 mg/ are only poody characteriz(.<l.
    [Show full text]
  • Psychedelics
    1521-0081/68/2/264–355$25.00 http://dx.doi.org/10.1124/pr.115.011478 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:264–355, April 2016 Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ERIC L. BARKER Psychedelics David E. Nichols Eschelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina Abstract ...................................................................................266 I. Introduction . ..............................................................................266 A. Historical Use . ........................................................................268 B. What Are Psychedelics?................................................................268 C. Psychedelics Can Engender Ecstatic States with Persistent Positive Personality Change . ..................................................................271 II. Safety of Psychedelics......................................................................273 A. General Issues of Safety and Mental Health in Psychedelic Users.......................275 B. Adverse Reactions . ..................................................................276 C. Hallucinogen Persisting Perception Disorder . ..........................................277 D. N-(2-methoxybenzyl)-2,5-dimethoxy-4-substituted phenethylamines (NBOMe) Compounds............................................................................278 Downloaded from III. Mechanism of Action.......................................................................279
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,877,755 B2 Barberich (45) Date of Patent: Nov
    US008877755B2 (12) United States Patent (10) Patent No.: US 8,877,755 B2 Barberich (45) Date of Patent: Nov. 4, 2014 (54) DOPAMINE-AGONIST COMBINATION 2002fOO19398 A1 2/2002 Jerussi et al. ................. 514,249 THERAPY FOR IMPROVING SLEEP 2002/014301.6 A1 10, 2002 Jerussi et al. ................. 514,249 QUALITY 2002fO165246 A1 11/2002 Holman 2002/0193378 A1 12/2002 Cotrel et al. .................. 514,249 2003.01.19841 A1 6/2003 Jerussi et al. .. ... 514,249 (75) Inventor: Timothy J. Barberich, Concord, MA 2003/0166657 A1 9, 2003 Jerussi et al. ................. 514,249 (US) 2004, OO679.57 A1* 4, 2004 Jerussi et al. ............ 514,252.16 2004/O122104 A1 6, 2004 Hirsh et al. ................... 514,620 (73) Assignee: Sunovion Pharmaceuticals Inc., 2004/0132826 Al 72004 Hirsh et al..... ... 514,620 Marlborough, MA (US) 2004/O147521 A1 7/2004 Jerussi et al. .. ... 514,249 s 2005, OO31688 A1 2/2005 Ayala ............. ... 424/473 - 2005/003.8042 A1 2/2005 Codd et al. ................. 514,259.1 (*) Notice: Subject to any disclaimer, the term of this 2005, 0164987 A1 7, 2005 Barberich et al. patent is extended or adjusted under 35 2005/0176680 A1 8/2005 Lalji et al. U.S.C. 154(b) by 723 days. (Continued) (21) Appl. No.: 12/541,686 FOREIGN PATENT DOCUMENTS (22) Filed: Aug. 14, 2009 EP 1742624 B1 1, 2010 WO WOOO25821 A1 * 5, 2000 (65) Prior Publication Data (Continued) US 201O/OOO4251A1 Jan. 7, 2010 OTHER PUBLICATIONS Related U.S. Application Data Earley, “Restless Legs Syndrome'. The New England Journal of (62) Division of application No.
    [Show full text]
  • The History and Pharmacology of Dopamine Agonists X
    THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES The History and Pharmacology of Dopamine Agonists X. Lataste ABSTRACT: The recognition of the dopaminergic properties of some ergot derivatives has initiated new therapeutical approaches in endocrinology as well as in neurology. The pharmacological characterization of the different ergot derivatives during the last decade has largely improved our understanding of central dopaminergic systems. Their development has yielded valuable information on the pharmacology of dopamine receptors involved in the regulatory mechanisms of prolactin secretion and in striatal functions. The clinical application of such new neurobiological concepts has underlined the therapeutical interest of such compounds either in the control of prolactin-dependent endocrine disorders or in the treatment of parkinsonism. Owing to their pharmacological profiles, dopaminergic agonists represent a valuable clinical option especially in the management of Parkinson's disease in view of the problems arising from chronic L-Dopa treatment. RESUME: L'identification des proprietes dopaminergiques de certains derives de l'ergot a permis d'envisager de nouvelles approches therapeutiques tant en endocrinologie qu'en neurologic Au cours des dix dernieres annees, la caracterisation de leurs differents profils pharmacologiques, souvent complexes, a largement contribue au developpement de nos connaissances sur les meCanismes dopaminergiques qui regissent la regulation de la secretion de prolactine ainsi que la regulation striatale des activites motrices. De plus, le developpement de derives ergotes dopaminomimetiques a permis l'identification des differents sites recepteurs de la dopamine. L'application clinique de ces nouveaux concepts neurobiologiques a revele l'interet porte a ces substances notamment dans le controle des desordres endocriniens prolactino-dependants ainsi que dans le traitement de la maladie de Parkinson.
    [Show full text]
  • Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds As a Basis of Their Therapeutic Application
    CHAPTER I Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic Application B. BERDE and E. STURMER "Truth is rarely pure and never simple" OSCAR WILDE This chapter, rather unorthodox for a volume of the Handbook of Experimental Pharmacology, is not intended as a summary of the wealth of information accumu- lated in this book. It is an attempt at a compact synopsis to help those teaching pharmacology or writing a textbook of pharmacology not to overlook the essential chemical and biological basis of the therapeutically most important compounds and those of their activities which are believed to be relevant for their therapeutic effects. The present volume, entitled Ergot Alkaloids and Related Compounds, deals with chemical entities containing the tetracyclic ergolene- or ergoline-ring system. They can be obtained by extraction of different strains of the fungus cIaviceps- grown on rye or cultivated in fermentation tanks-or alternatively by partial or total synthesis. These compounds can be divided into four main structural groups: cIavine alkaloids, lysergic acids, simple lysergic acid-amides, and peptide alkaloids. One example of each type of molecule is given in Figure 1. The degree of oxidation is a criterion for further differentiation in the group of cIavine alkaloids, all of which are compounds of minor biological importance. The naturally occurring lysergic acids are divided into compounds with a double bond in the 8-9 position (8-ergolenes) and in the 9-10 position (9-ergolenes). All congeners are methylated in position (i. The two asymmetric carbon atoms in position 5 and 10 (in the case of 8-ergolenes) or 5 and 8 (in the case of Glavine-Alkaloids Lysergic Acid group Lysergic Acid Amides Peptide-Alkaloids of Alkaloids Examples: I'_ GOOH I"'" NH'GH3 b ~HN Elymoclavine D-Lysergic Acid Ergometrine Ergotamine Fig.
    [Show full text]
  • Bromocriptine Alone Or Associated with L-Dopa Plus Benserazide in Parkinson's Disease
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.40.12.1142 on 1 December 1977. Downloaded from Journal ofNeurology, Neurosurgery, andPsychiatry, 1977, 40, 1142-1146 Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease T. A. CARACENI, I. CELANO, E. PARATI, AND F. GIROTTI From the Istituto Neurologico 'C. Besta', Milan, Italy S U M M A R Y Twenty-six patients affected by Parkinson's disease were treated with a 2-Br-alpha- ergocriptine (CB 154): 14 cases were given CB 154 alone, and 12 were given CB 154 along with L-dopa plus benserazide (Madopar). Both CB 154 and combined therapy (CB 154+Madopar) induced a significant improvement in total disability score, tremor, rigidity, akinesia, self- sufficiency, and some motor performance tests (dynamic tests). No significant difference was found between results obtained with CB 154 therapy and with Madopar treatment, while the improvement induced by combined therapy (CB 154 +Madopar) was significantly higher than that obtained by Madopar alone. The adverse reactions caused by CB 154 alone or associated with Madopar are similar to those observed during other dopaminergic treatment. CB 154 aloneby guest. Protected copyright. or combined with Madopar appears to be a useful advance in the management of Parkinson's disease. 2-bromo-a-ergocriptine (CB 154) is an ergot longer responding to L-dopa. The addition of alkaloid which has been proved effective in caffeine did not enhance the antiparkinsonism suppressing lactation and inhibiting prolactin potency of ergocriptine (Kartzinel et al., 1976b). secretion (Fluckiger and Wagner, 1968; Billiter Taking this diversity of opinions regarding the and Fluckiger, 1971).
    [Show full text]
  • Management of Parkinson's Disease: an Evidence-Based Review
    Movement Disorders Vol. 17, Suppl. 4, 2002, p. i 2002 Movement Disorder Society Published by Wiley-Liss, Inc. DOI 10.1002/mds.5554 Editorial Management of Parkinson’s Disease: An Evidence-Based Review* Although Parkinson’s disease is still incurable, a large number tomatic control of Parkinson’s disease; prevention of motor com- of different treatments have become available to improve quality plications; control of motor complications; and control of non- of life and physical and psychological morbidity. Numerous jour- motor features. Based on a systematic review of the data, efficacy nal supplements have appeared in recent years highlighting one conclusions are provided. On the basis of a narrative non-system- or more of these and disparate treatment algorithms have prolifer- atic approach, statements on safety of the interventions are given ated. Although these are often quite useful, this “mentor analy- and finally, a qualitative approach is used to summarize the impli- sis” approach lacks the scientific rigor required by modern evi- cations for clinical practice and future research. dence-based medicine standards. The Movement Disorder Soci- This mammoth task has taken two years to complete and the ety, with generous but unrestricted support from representatives task force members, principal authors and contributors are to be of industry, have, therefore, commissioned a systematic review congratulated for their outstanding work. Physicians, the of the literature dealing with the efficacy and safety of available Parkinson’s disease research community and most of all patients treatments. The accompanying treatise is the result of a scrupu- themselves should welcome and embrace the salient findings of lous evaluation of the literature aimed at identifying those treat- this report as an effort to improve clinical practice.
    [Show full text]
  • Bromocriptine Treatment in Parkinson's Disease
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.39.2.184 on 1 February 1976. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry, 1976, 39, 184-193 Bromocriptine treatment in Parkinson's disease J. D. PARKES, C. D. MARSDEN, I. DONALDSON, A. GALEA-DEBONO, J. WALTERS, G. KENNEDY, AND P. ASSELMAN From the University Department of Neurology, The Institute of Psychiatry, anzd King's College Hospital, London SYNOPSIS Thirty-one patients with Parkinson's disease were treated with the ergot alkaloid bromocriptine, a drug which stimulates dopamine receptors. Bromocriptine had a slight therapeutic effect in patients on no other treatmnent and an additional effect in patients on levodopa. The mean optimum dosage of bromocriptine, established over a 12 week period, was 26 mg daily. In 20 patients bromocriptine was compared with placebo in a double-blind controlled trial. Active treat- ment caused a significant (P <0.02) reduction in total disability and akinesia scores. The least disabled patients showed the greatest response. Side-effects of bromocriptine-nausea, vomiting, hallucinations, and abnormal involuntary movements-were similar in nature to those of levodopa.guest. Protected by copyright. In most normal subjects, bromocriptine causes an increase in plasma growth hormone concentration. This was determined in 20 patients with Parkinson's disease after 1-15 mg bromocriptine. Only a single patient showed an obvious increase up to 120 minutes after dosage. Bromocriptine was not effective treatment in two patients who had not previously responded to levodopa and replacement of this drug by bromocriptine in patients with end-of-dose akinesia after chronic levodopa treatment did not totally abolish response swings.
    [Show full text]